a popular therapeutic option in United States (38%). The reasons for treatment differences and treatment efficacy were not explored, but we speculate that influences on prescribing may include local customs, availability of treatment, cost, and patient preferences. In addition, dermatologists and gynecologists may see a different spectrum of disease. These data show that physicians might consider expanding their treatment options beyond the current standard practice for their respective regions. The information from this survey will be helpful in designing future international collaborative studies to assess efficacy of treatments for vulvovaginal LP.
A Comparison of 2 Brief Intervention Approaches to Reduce Indoor Tanning Behavior in Young Women Who Indoor Tan Very Frequently
C ase-control studies have found evidence linking UV radiation exposure through indoor artificial UV tanning to all forms of skin cancer, and these risks increase exponentially for those who indoor tan more than 10 times a year. 1, 2 Compounding the problem are the high rates of indoor UV tanning among young women, who engage in significantly more indoor tanning than men. 3, 4 Despite these risks, few prevention efforts have been developed specifically targeting indoor tanners who tan very frequently. The present pilot study tested the efficacy of 2 brief intervention approaches, shown to be successful in modifying other difficult-to-change health behaviors, in reducing very frequent indoor tanning behavior in young women: (1) the peer-delivered Motivational Interview 5 (PMI) and (2) personalized graphic feedback (PGF). 6 The PMI uses a one-on-one, 30-minute counseling session to provide cognitive-behavioral skills information and help participants evaluate the effects of current indoor tanning behaviors with the aim of enhancing their desire to reduce harmful behaviors. The benefit of the PMI is that the health and appearance information can be tailored to the salient aspects of the participants' concerns. The PMI uses a personalized graphic feedback sheet that incorporates information on the participants' indoor tanning behaviors, normative beliefs about tanning, beliefs about tanning effects, tanning-related problems, tanning financial costs, family history of skin cancers, and skin-protective behaviors ( Figure) .
The PGF uses the same feedback sheet used in the PMI (Figure) but is delivered via mail with no person-toperson contact. To ensure that our subjects read the PGF material, we had them log on to a secured Web site and answer questions regarding its content. A benefit of the PGF is its low cost and ease of implementation, making it potentially more sustainable than the PMI. We hypothesized that individuals completing either of the 2 interventions (PMI or PGF) would engage in fewer indoor tanning sessions than subjects in a nonintervention control group during the 3-month postintervention follow-up period.
Methods. Participants were all undergraduates drawn from an introductory health course often taken as a general education requirement at a large northeastern US university. They were offered course extra credit and a nominal payment in exchange for their participation. The eligibility requirements were female sex and having indoor tanned 10 or more times in the past year. Of the initial 245 participants invited to take a baseline screen assessment consisting of questions on skin type, number of indoor tanning sessions within the past year, and intentions to tan, 105 met the eligibility criteria and were randomly assigned to conditions (39, PMI; 34, PGF; and 32, a no-intervention control group). No significant differences between the groups were observed at baseline with regard to number of indoor tanning sessions the previous winter, skin type, or measures of attitudes toward indoor tanning (P Ͼ .05 for all categories). Interventions were administered during the month of November. The university institutional review board approved the research protocol.
Results. Between-group analysis of variance was used to compare the conditions on 3-month postintervention total number of indoor tanning sessions during the months of December, January, and February. These months were chosen because we believe they are generally the months of most frequent indoor tanning activity in the geographic area of the university. Significant differences between the conditions were observed (F 2,102 =4.05, PϽ.02, 2 = 0.07). Follow-up comparisons using the TukeyKramer 7 post hoc test revealed a significant difference (PϽ.006) between the mean (SD) number of indoor tanning sessions during December through February for the PMI group (4.40 [7.74] ) and the control group (11.78 [13.03]). We also observed a difference between the mean (SD) number of indoor tanning sessions during December through February for the PGF group (9.03 [11.92]) and the PMI group, although the difference was not significant (P Ͻ .08). No significant difference was observed between the PGF and control groups.
Comment. The indoor tanning behavior of participants in the PMI group was markedly reduced compared with the behavior of those in the control and PGF groups, possibly because the nonjudgmental session with a trained PMI peer counselor provided information not provided to the control or PGF participants. In interventions that use peer counselors, the participant's behavior change may be influenced by identification with the counselor and/or by the validation and support provided by the counselor to aid in reducing risky behaviors.
It is unclear which components of the PMI (appearance concerns, health concerns, or both) were most effective in reducing indoor tanning sessions or if it was the combination of all aspects that led to behavior change. More research is needed to identify mediational components involved with behavior change. However, the PMI approach is a low-cost, sustainable, and potentially effective technique that could be integrated into existing university health or residential life programs that use peer counselors to reduce indoor tanning behaviors in a high-risk population.
Despite the positive effects identified, some limitations to the research must be considered. First, our convenience sample of participants may have introduced some bias into the results. Second, the follow-up period was brief and did not permit the examination of the potential for decay in the observed effects. Third, the brevity of the outcome assessments did not permit a formal examination of the underlying sources of change (eg, health or appearance motives, both, or other mechanisms). Fourth, significant intervention effects were not found for the PGF despite a reduction in indoor tanning behaviors by almost 25% at follow-up. We believe that this may be owing to a lack of power caused by the small sample size. Despite the limitations, the current study highlights the promise of such interventions, which warrant further examination on a larger scale.
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Report of a Case.
A 70-year-old woman with stage IV non-small cell lung cancer was evaluated regarding a 2-year history of scalp erythema and crusting that progressed to scarring alopecia (Figure 1) . The eruption began 8 months after the start of gefitinib therapy, 250 mg/d. However, textural changes and slower hair growth were noted after only 2 months of gefitinib treatment.
A 4-mm punch biopsy specimen from an erythematous scaly area on the scalp vertex showed parakeratosis with focal follicular plugging containing neutrophils. Periodic acid-Schiff staining did not reveal fungi or basement membrane thickening. Superficial dermal edema was present (Figure 2A, main image) ; results of a Hale stain for mucin were negative. A chronic inflammatory infiltrate, consisting mostly of plasma cells with some lymphocytes, was seen focally distributed within the dermis. Fibrosis consistent with scarring obscured the upper portion of hair follicles. Abundant collagen was seen under trichrome-Masson stain (Figure 2A , inset). Mature anagen hairs were present in the subcutaneous fat; they were surrounded by numerous plasma cells, a few lymphocytes and eosinophils, and rare neutrophils ( Figure 2B ). Repeated bacterial cultures from swabs proved negative.
The patient's rapidly progressive disease led to gefitinib treatment being discontinued soon after the scalp biopsy procedure. The effect on hair regrowth of discontinuing gefitinib treatment was not possible to evaluate because the patient died of widespread metastatic disease 2 weeks later.
Comment. The rapid acquisition of hair textural changes along with the histopathologic characteristics of the present case favored a diagnosis of scarring alopecia secondary to gefitinib. The main differential diagnosis was folliculitis decalvans, although the notable plasma cell and eosinophilic cell infiltrate along with absence of Staphylococcus in repeated swabs and cultures suggested a distinct drug-related process. Because the patient died so soon after therapy was discontinued, we could not evaluate the effect of stopping treatment and thus make a more definitive assessment about the role of gefitinib.
Graves et al 4 first described a patient who developed nonscarring alopecia after 2 years of undergoing gefitinib therapy. Their patient differed from ours in that she was evaluated within a few months of first noticing hair loss rather than many years later. Furthermore, scarring was not present, and hair regrowth was observed after gefitinib treatment was stopped. It is possible that the changes reported by Graves et al 4 represent the earliest changes of gefitinib-induced alopecia and that with time, a scarring alopecia may result. Wu et al 5 described a 69-year-old woman who developed scarring alopecia following initiation of gefitinib treatment and scalp radiotherapy. A scalp biopsy specimen also revealed an inflammatory infiltrate of mainly plasma cells. The patient was diagnosed as having erosive pustular dermatosis of the scalp. A rapid improvement was noted with the use of topical steroids despite continuation of gefitinib treatment. Whether this was a different condition than we observed in our patient is unknown. The notable plasma cell infiltrate findings would suggest a similar process, although the depth of the infiltrate, the presence of eosinophils, and the more marked fibrosis observed in our patient raise the possibility of a different process. 
